ERBB2 and non-small cell lung carcinoma: The same is true for EGFR T790M non-small-cell lung cancer that is osimertinib-resistant with 6% of patients bearing ERBB2 amplification (Safran et al, 2022; Takeda and Nakagawa, 2019; Vallillo et al., 2020; Soria et al,2018; Sun and Osimertinib, 2018; Monica et al 2017; Zhu et al 2020; Tang, 2018).